Development and validation of a novel nomogram for predicting outcomes in advanced lung cancer patients treated beyond progression with immune checkpoint inhibitors
This validated nomogram provides a clinically actionable tool to identify patients benefiting from sustained ICIs exposure, enabling pharmacologically informed TBP strategies while minimizing futile drug exposure. Future prospective multicenter studies should validate utility across diverse pharmacogenomic populations.
Authors
- Ying Zhao (ORCID: https://orcid.org/0000-0002-6436-671X)
- Mi Yang (ORCID: https://orcid.org/0000-0001-6842-2769)
- Tianwei Luo
- Ning Han (ORCID: https://orcid.org/0000-0001-8177-2843)
- Ting Ouyang
- Genwang Wang
- Ao Chen (ORCID: https://orcid.org/0000-0002-5844-6748)
- Chao Chen (ORCID: https://orcid.org/0000-0001-9526-0099)
- Xiufeng Liu (ORCID: https://orcid.org/0000-0002-1599-2474)
- Haiyun Geng
Institutions
- Nanjing Drum Tower Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1643591
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Nanjing University